Pioneering precision therapies for inherited channelopathies, cardiometabolic diseases and cardiomyopathies
Next-generation investigational SGK1 inhibitors targeting electrical instability and residual risk
ENROLLING SOON
A Phase 2a study of THRV-1268 in heart failure
ASPIRE-HF will evaluate investigational THRV-1268 in heart failure with reduced ejection fraction (HFrEF).
WHAT WE’RE STUDYING NOW
Targeting electrical instability and residual risk in two diseases with high unmet need
ASPIRE-HF: A Phase 2a study of THRV-1268 in participants living with heart failure with reduced ejection fraction (HFrEF).
Wave II: A Phase 2/3 study of THRV-1268 in participants aged 15 and older with Long QT Syndrome Type 2 and Type 3.
WHO WE ARE
Pioneering next-generation precision therapies for inherited channelopathies, cardiometabolic diseases and cardiomyopathies
A clinical-stage biotechnology company advancing a portfolio of potent, selective inhibitors of serum and glucocorticoid-regulated kinase 1 (SGK1) as precision medicines for inherited channelopathies, cardiometabolic diseases and cardiomyopathies.
Human genetic and patient-level data validate SGK1 as a core target for addressing residual risk across cardiovascular diseases.
Thryv’s lead candidate, THRV-1268, is being studied in Wave II, a Phase 2/3 study enrolling people with Long QT Syndrome Type 2 and Type 3. ASPIRE-HF, a Phase 2a study in heart failure with reduced ejection fraction (HFrEF), is enrolling soon.
WHY SGK1
Genetically-validated cardiometabolic disease node
Despite guideline-directed medical therapy, patients living with Long QT Syndrome, heart failure and other conditions remain at high risk of hospitalization, potentially lethal arrhythmias, and mortality. SGK1 drives pathological electrical and structural remodeling that can cause continued disease progression and poor outcomes.
Electrical instability
Delayed repolarization and QTc prolongation on the ECG, increasing the risk of potentially lethal ventricular arrhythmias.
Inflammation & fibrosis
SGK1 activation triggers an inflammatory and fibrosis cascade in the heart.
Adverse structural remodeling
Continued dysfunction in contractility, relaxation, and structural remodeling
→ SGK1 inhibition targets these core disease pathways.
Human genetic validation
Lower ventricular SGK1 expression is associated with reduced heart failure risk.
In the UK Biobank, a rare SGK1 variant was significantly associated with heart failure.
These human genetic findings validate SGK1 as a core disease node to target persistent electrical, functional, and structural disease abnormalities in heart failure and cardiomyopathies.
THRV-1268 is an investigational drug and has not been approved by any regulatory authority. Its safety and efficacy have not been established.
In memory of Isla Hutton (LQT3)
We gain momentum every day in our relentless pursuit of a treatment for Long QT Syndrome, in memory of Isla.
Together We Thryv
